Wuhan Coronavirus Thread

[Jimih]

Approval for Covaxin was also asked. Did these countries added Covaxin too?

Not for now

 

[johnq]

Dear Johnq ji , can we have a separate Lab Leak/Bioweapon thread to give it the eyeballs it deserves?

I would rather have everything in one thread because it's all connected.

 

[johnq]

Uncovering the Origins of COVID-19: A Scientific Discussion

 

[johnq]

GOP Medical Witnesses: COVID-19 'Exactly What You'd Expect If You'd Gone Through Gain-Of-Function'

 

[johnq]

'Suddenly You Can't Find Him': Jim Jordan Criticizes Fauci For Skipping GOP COVID-19 Origin Hearing

 

[johnq]

JUST IN: Jim Jordan Attacks Fauci's Actions At Start Of COVID-19 Pandemic

 

[mandestiny]

Not for now

Some EU countries start adding both Indian vaccine. Please see news.

 

[mandestiny]

Approval for Covaxin was also asked. Did these countries added Covaxin too?

Some EU countries start adding both Indian vaccine. Please see news.

 

[johnq]

 

[johnq]

The tide is starting to turn in US mainstream media.

Wuhan lab researcher linked to military scientists, NBC News finds

In January, a Trump administration fact sheet accused China of “secret military activity” at a lab in Wuhan. Dr. Shi Zhengli, a leading researcher at the Wuhan Institute of Virology, says it is a civilian institution, but NBC News has found evidence of her connections with military scientists.

www.nbcnews.com

In January, a Trump administration fact sheet accused China of “secret military activity” at a lab in Wuhan. Dr. Shi Zhengli, a leading researcher at the Wuhan Institute of Virology, says it is a civilian institution, but NBC News has found evidence of her connections with military scientists.

 

[captscooby81]

I feel these are tough action like tactics from sleepy govt to negotiate a bigger better deal with bat munchers . nothing will come out of these investigations . Uncle 11 ping will offer a better deal for wall street thugs and sleepy will say all is well and shake hands and move on .

Rest of world will get babaji ka thullu

The tide is starting to turn in US mainstream media.

Wuhan lab researcher linked to military scientists, NBC News finds

In January, a Trump administration fact sheet accused China of “secret military activity” at a lab in Wuhan. Dr. Shi Zhengli, a leading researcher at the Wuhan Institute of Virology, says it is a civilian institution, but NBC News has found evidence of her connections with military scientists.

www.nbcnews.com

In January, a Trump administration fact sheet accused China of “secret military activity” at a lab in Wuhan. Dr. Shi Zhengli, a leading researcher at the Wuhan Institute of Virology, says it is a civilian institution, but NBC News has found evidence of her connections with military scientists.

 

[johnq]

I feel these are tough action like tactics from sleepy govt to negotiate a bigger better deal with bat munchers . nothing will come out of these investigations . Uncle 11 ping will offer a better deal for wall street thugs and sleepy will say all is well and shake hands and move on .

Rest of world will get babaji ka thullu

While I agree with what you said about the sleepy govt, I think there is a kind of anger building up among the American people due to 600,000+ deaths and the truth starting to leak out about the CCP bioweapon virus (and the coverup assisted by the US leftist establishment and even leftist scientists), which may cause dumbocrats to lose power in the long run, as well as helping people who understand the evil of the CCP to get into political positions. The truth seekers and whistleblowers about the CCP virus may end up winning the long game after all, because the American people are starting to wake up to the truth of how wall street/ US leftist establishment is batting for CCP.

 

[sorcerer]

Robust, mobile OxyJani can cater to acute & chronic oxygen needs at grassroots level


Posted On: 01 JUL 2021 5:56PM by PIB Delhi



Indian researchers have designed a robust, mobile group oxygen concentrator that can be used in rural settings and also be rapidly deployed in emergencies in any location.





The second wave of COVID-19 led to an acute shortage of medical oxygen. While the crisis in the bigger cities was more about rapidly responding by overcoming supply chain limitations, in smaller cities and villages, the crisis exposed the chronic lack of medical oxygen infrastructure in the country.





Overcoming the crisis required two types of solutions -- 5 to 10 lpm personalized O2 concentrators for home uses and 500 lpm PSA plants for large hospitals. While the 500 Ipm plants for hospitals were robust, they lacked the portability required for deployment on resource-poor settings, while personal concentrators were too fragile to be used on a sustained basis in a hospital setting. This created a need for a robust technology with necessary portability.





A team from Jawaharlal Nehru Centre for Advanced Scientific Research, an autonomous institute under the Department of Science & Technology, Government of India, developed a new solution with the name ‘OxyJani’ for addressing these novel challenges in adsorption science and engineering.





It was developed during the second wave of COVID-19, addressing the several novel design challenges posed for the sourcing of materials and the need in hospitals of different capacities.


OxyJani is based on the principles of Pressure Swing Adsorption (PSA) technology. The team replaced lithium zeolites (LiX) which is usually used in oxygen concentrators, with sodium zeolites which does not generate toxic solid waste and can be manufactured in India.





Although the science behind it is well understood, developing an engineering solution that can work with sodium in a portable device and fill this specific market gap when there are severe sourcing problems posed engineering challenges. Obstacles had to be overcome at each stage of the cycle, from working with the available zeolites to effective ways of dehumidifying and designing the right adsorption-pressure cycle.





The concentrator is modular and capable of delivering a range of solutions, conversion of medical air to medical oxygen, and is an entirely off-grid solution including all modules that can facilitate deployment in rural areas. Moreover, the waste from the 13X zeolite plant can be potentially a good agricultural input material.





In this multi-group initiative, Dr S. V. Diwakar, Dr Meher Prakash, Professor Santosh Ansumali from JNCASR, and collaborators, Professor Arvind Rajendran from the University of Alberta and Mr. Arun Kumar (Eiwave Digitech) executed the OxyJani developmental efforts with the help of Mr. Ritwik Das (MS student). Technical advice was provided by Prof. M. Eswaramoorthy, Prof. Tapas Maji, and Prof. Sridhar Rajaraman. Professor G. U. Kulkarni, President, JNCASR and Professor Amitabha Bandyophyay of IIT Kanpur mentored developmental efforts. The financial assistance for the prototype was provided through JNCASR and the Nidhi Prayaas scheme of IIT Kanpur. The zeolite material was obtained through a generous donation from Honeywell UOP, Italy.





This new class of technology called “group concentrators” has the robustness of large PSA plants, portability similar to the personal concentrators, and is affordable too. The device is in the range of 30-40 lpm, which is potentially useful for ICU uses too.

Figure. A modular design of the three different units so that solutions can be offered to different hospitals based on their needs.

 

[sorcerer]

‘Mulethi’ may help alleviate aggressive symptoms of COVID-19--India Science Wire
By India Science Wire

4-5 minutes

Mulethi

In an interesting development, a team of scientists at the Government of India’s Department of Biotechnology (DBT)’s National Brain Research Centre (NBRC), has identified Mulethi, a commonly used herb, as a potential source for the development of a drug against COVID-19.

Scientists have found that an active ingredient in the root of the herb called Glycyrrhizin lowered the severity of the disease and brought down viral replication.

The finding assumes importance as there is still no specific drug to treat Covid-19 infection even while several vaccines have come up. The doctors currently manage with a few repurposed medicines.

The NBRC team started looking for a drug against Covid-19 last year. They studied Mulethi as it was known to have excellent anti-inflammatory properties. They carried out a series of experiments to check its potential against the COVID virus.

In an interesting development, a team of scientists at the Government of India’s Department of Biotechnology (DBT)’s National Brain Research Centre (NBRC), has identified Mulethi, a commonly used herb, as a potential source for the development of a drug against COVID-19.

When the COVID virus infects human cells, the body’s immune system reacts by releasing a set of proteins called cytokines. In the case of a severe infection, the immune cells respond rapidly by releasing a “storm of cytokines”. Sometimes this can become uncontrolled leading to severe inflammation and fluid accumulation in lung tissues. This condition may lead to acute respiratory distress, cell death, and eventually, organ failure.

The NBRC scientists found that glycyrrhizin molecules in Mulethi could help avoid this problem. The researchers expressed specific viral proteins in human lung epithelial cells. The proteins triggered inflammation in these cells. Treatment with glycyrrhizin cleared the inflammation. The untreated cells succumbed to inflammation.

The scientists analysed the molecule further and found that apart from inhibiting the cytokine storm, glycyrrhizin also reduces viral replication by 90%. Mulethi is widely prescribed for lung ailments, chronic fevers and respiratory tract inflammation in Ayurveda, glycyrrhizin is used in the treatment of chronic hepatitis B and C.

“Given its safety profile and tolerability, Mulethi might constitute a viable therapeutic option in patients with SARS-CoV-2 infection,” scientists said. The team is now looking for partners to carry forward the research into the preclinical stage. They have published a report on their study in Cytokine, the official journal of the International Cytokine and Interferon Society. Senior scientist Ellora Sen, conducted the study with her fellow researchers Pruthvi Gowda, Shruti Patrick, Shanker Datt, Rajesh Joshi, and Kumar Kumawat.

Keywords: Department of Biotechnology, DBT, root, Glycyrrhizin, disease, viral replication, repurposed medicines, anti-inflammatory, immune system, proteins, cytokines, fluid, lung, tissue, respiratory, organ, epithelial cells.

 

[Nicky G]

Why did we stop using Ivermectin?

 

[Nicky G]

Kadian Pappu covering up?

 

[doreamon]

‘Mulethi’ may help alleviate aggressive symptoms of COVID-19--India Science Wire
By India Science Wire

4-5 minutes

Mulethi

In an interesting development, a team of scientists at the Government of India’s Department of Biotechnology (DBT)’s National Brain Research Centre (NBRC), has identified Mulethi, a commonly used herb, as a potential source for the development of a drug against COVID-19.

Scientists have found that an active ingredient in the root of the herb called Glycyrrhizin lowered the severity of the disease and brought down viral replication.

The finding assumes importance as there is still no specific drug to treat Covid-19 infection even while several vaccines have come up. The doctors currently manage with a few repurposed medicines.

The NBRC team started looking for a drug against Covid-19 last year. They studied Mulethi as it was known to have excellent anti-inflammatory properties. They carried out a series of experiments to check its potential against the COVID virus.



When the COVID virus infects human cells, the body’s immune system reacts by releasing a set of proteins called cytokines. In the case of a severe infection, the immune cells respond rapidly by releasing a “storm of cytokines”. Sometimes this can become uncontrolled leading to severe inflammation and fluid accumulation in lung tissues. This condition may lead to acute respiratory distress, cell death, and eventually, organ failure.

The NBRC scientists found that glycyrrhizin molecules in Mulethi could help avoid this problem. The researchers expressed specific viral proteins in human lung epithelial cells. The proteins triggered inflammation in these cells. Treatment with glycyrrhizin cleared the inflammation. The untreated cells succumbed to inflammation.

The scientists analysed the molecule further and found that apart from inhibiting the cytokine storm, glycyrrhizin also reduces viral replication by 90%. Mulethi is widely prescribed for lung ailments, chronic fevers and respiratory tract inflammation in Ayurveda, glycyrrhizin is used in the treatment of chronic hepatitis B and C.

“Given its safety profile and tolerability, Mulethi might constitute a viable therapeutic option in patients with SARS-CoV-2 infection,” scientists said. The team is now looking for partners to carry forward the research into the preclinical stage. They have published a report on their study in Cytokine, the official journal of the International Cytokine and Interferon Society. Senior scientist Ellora Sen, conducted the study with her fellow researchers Pruthvi Gowda, Shruti Patrick, Shanker Datt, Rajesh Joshi, and Kumar Kumawat.

Keywords: Department of Biotechnology, DBT, root, Glycyrrhizin, disease, viral replication, repurposed medicines, anti-inflammatory, immune system, proteins, cytokines, fluid, lung, tissue, respiratory, organ, epithelial cells.

Coronil had mulethi as a ingredient ... Patanjali shd invest in scientific validation of ayurvedic product along with discovering the active molecules there in .. It ll help generate new medicines acceptable on a global level .

 

[Jimih]

Now DNA vaccine

 

[johnq]

Why did we stop using Ivermectin?

All related to money and profit. Cheap drugs like Ivermectin and Hydroxychloroquine available widely were rejected by the W.H.O. and the big drug companies/cartels in favor of new expensive drugs like Remdesivir which kills the liver and is far less effective.

 

[Jimih]

Judicial Activism from Milaards